The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances.
Photodynamic therapy (PDT) is a promising modality for the treatment of both pre-malignant and malignant lesions. The mechanism of action converges mainly on the generation of reactive oxygen species which damage cancer cells directly as well as indirectly acting on tumor vasculature. The exact mechanism of PDT action is not fully understood, which is a formidable barrier to its successful clinical application. Elucidation of the mechanisms of cancer cell elimination by PDT might help in establishing highly specific, non-genotoxic anti-cancer treatment of tomorrow. One of the candidate PDT targets is the well-known tumor suppressor p53 protein recognized as the guardian of the genome. Together with its family members, p73 and p63 proteins, p53 is involved in apoptosis induction upon stress stimuli. The wild-type and mutant p53-targeting chemotherapeutics are currently extensively investigated as a promising strategy for highly specific anti-cancer therapy. In photodynamic therapy porphyrinogenic sensitizers are the most widely used compounds due to their potent biophysical and biochemical properties. Recent data suggest that the p53 tumor suppressor protein might play a significant role in porphyrin-PDT-mediated cell death by direct interaction with the drug which leads to its accumulation and induction of p53-dependent cell death both in the dark and upon irradiation. In this review we describe the available evidence on the role of p53 in PDT.
Zawacka-Pankau
Joanna
J
Department of Biotechnology, Division of Molecular Diagnostics, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Kladki 24, 80-822 Gdansk, Poland. jzawacka@biotech.ug.gda.pl
Krachulec
Justyna
J
Grulkowski
Ireneusz
I
Bielawski
Krzysztof P
KP
Selivanova
Galina
G
D017209:Apoptosis / Q000187:drug effects; D018797:Cell Cycle Proteins; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009687:Nuclear Proteins / Q000502:physiology; D010778:Photochemotherapy; D011518:Proto-Oncogene Proteins / Q000502:physiology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000502:physiology; D011524:Protoporphyrins / Q000494:pharmacology; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000502:physiology*
D018797:Cell Cycle Proteins; C482775:MDM4 protein, human; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D011524:Protoporphyrins; D016159:Tumor Suppressor Protein p53; C028025:protoporphyrin IX; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2